Sinonasal undifferentiated carcinoma: Institutional trend toward induction chemotherapy followed by definitive chemoradiation.
definitive chemoradiation
induction chemotherapy
sinonasal undifferentiated carcinoma
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
24
01
2020
revised:
17
05
2020
accepted:
16
06
2020
pubmed:
19
7
2020
medline:
22
6
2021
entrez:
19
7
2020
Statut:
ppublish
Résumé
Recent reports have investigated the nascent role of induction chemotherapy for sinonasal undifferentiated carcinoma (SNUC). The goal of this study was to ascertain trends in treatment pattern changes for SNUC at a single institution and design a treatment algorithm utilized at our institution. Retrospective chart analysis of 21 cases of SNUC from 2010 to 2018. Of 21 patients in this cohort, 18 (85.7%) presented with T4 disease, 7 (33.3%) presented with nodal disease, and 3 (14.3%) presented with distant metastasis. Since 2016, patients have been managed by induction chemotherapy followed by concurrent chemoradiation. To this point, patients treated with TPF induction chemotherapy followed by concurrent chemoradiation show no evidence of disease; however, the average follow up time is 16.8 months. The multimodality treatment for SNUC continues to evolve, as highlighted by this study, toward increased use of induction chemotherapy followed by chemoradiotherapy.
Sections du résumé
BACKGROUND
Recent reports have investigated the nascent role of induction chemotherapy for sinonasal undifferentiated carcinoma (SNUC). The goal of this study was to ascertain trends in treatment pattern changes for SNUC at a single institution and design a treatment algorithm utilized at our institution.
METHODS
Retrospective chart analysis of 21 cases of SNUC from 2010 to 2018.
RESULTS
Of 21 patients in this cohort, 18 (85.7%) presented with T4 disease, 7 (33.3%) presented with nodal disease, and 3 (14.3%) presented with distant metastasis. Since 2016, patients have been managed by induction chemotherapy followed by concurrent chemoradiation. To this point, patients treated with TPF induction chemotherapy followed by concurrent chemoradiation show no evidence of disease; however, the average follow up time is 16.8 months.
CONCLUSIONS
The multimodality treatment for SNUC continues to evolve, as highlighted by this study, toward increased use of induction chemotherapy followed by chemoradiotherapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3197-3205Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Amit M, Abdelmeguid AS, Watcherporn T, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504-512. https://doi.org/10.1200/JCO.18.00353.
Tyler MA, Holmes B, Patel ZM. Oncologic management of sinonasal undifferentiated carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2019;27:59-66. https://doi.org/10.1097/MOO.0000000000000513.
Chambers KJ, Lehmann AE, Remenschneider A, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base. 2015;76(2):94-100. https://doi.org/10.1055/s-0034-py1390016.
Musy PY, Reibel JF, Levine PA, et al. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8) Pt 1:1450-1455.
Gray ST, Herr MW, Sethi RK, et al. Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review. Head Neck. 2015;37(3):366-374. https://doi.org/10.1002/hed.23606.
Abdelmeguid AS, Bell D, Hanna EY. Sinonasal undifferentiated carcinoma. Curr Oncol Rep. 2019;21(3):26. https://doi.org/10.1007/s11912-019-0776-4.
Workman AD, Brody RM, Kuan EC, et al. Sinonasal undifferentiated carcinoma: a 15-year single institution experience. J Neurol Surg B. 2019;80:88-95.
Tanzler ED, Morris CG, Orlando CA, Werning JW, Mendenhall WM. Management of sinonasal undifferentiated carcinoma. Head Neck. 2008;30(5):595-599.
Al-Mamgani A, van Rooij P, Mehilal R, Tans L, Levendag PC. Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol. 2013;270(1):293-299.
Yoshida E, Aouad R, Fragoso R, et al. Improved clinical outcomes with multi-modality therapy for sinonasal undifferentiated carcinoma of the head and neck. Am J Otolaryngol. 2013;34(6):658-663.
Lopez F, Suárez V, Vivanco B, Suárez C, Llorente JL. Current management of sinonasal undifferentiated carcinoma. Rhinology. 2015;53(3):212-220.
Khan MN, Konthula N, Parasher A, et al. Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database. Int Forum Allergy Rhinol. 2017;7(2):205-210.
Barber E, Eapen A, Nabar R, Goreal W, Bunney J, Parajuli R. Treatment of sinonasal undifferentiated carcinoma with TPF and concurrent chemoradiation: case report and literature review. Case Rep Oncol. 2019;12:199-204. https://doi.org/10.1159/000496496.
Watanabe S, Honma Y, Murakami N, et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: two cases of report. World J Clin Cases. 2019;7(6):765-772. https://doi.org/10.12998/wjcc.v7.i6.765.
Elkhatib AH, Soldatova L, Carrau RL, et al. Role of 18F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. Laryngoscope. 2017;127(2):321-324. https://doi.org/10.1002/lary.26194.
Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498-506.
Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509-1520.
Bonomi M, Blakaj A, Blakaj D. Organ preservation for advanced larynx cancer: a review of chemotherapy and radiation combination strategies. Oral Oncol. 2018;86:301-306.
Ansari M, Guo S, Fakhri S, et al. Sinonasal undifferentiated carcinoma (SNUC): morphoproteomic-guided treatment paradigm with clinical efficacy. Ann Clin Lab Sci. 2013;43(1):45-53.
Zielinski V, Laban S, Tribius S, et al. Management of sinonasal undifferentiated carcinoma with intracerebral invasion: clinical experience at a single institution and review of the literature. Ear Nose Throat J. 2016;95(1):23-28.
Vermorken J, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704.
Posner J, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-1715.